Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) EBIT : $-1.81 Mil (TTM As of Jan. 2020)

View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals EBIT?

Cotinga Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Jan. 2020 was $-0.36 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jan. 2020 was $-1.81 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cotinga Pharmaceuticals's annualized ROC % for the quarter that ended in Jan. 2020 was -172.66%. Cotinga Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2020 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cotinga Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2020 was -544.74%.

Cotinga Pharmaceuticals EBIT Historical Data

The historical data trend for Cotinga Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals EBIT Chart

Cotinga Pharmaceuticals Annual Data

Trend

Apr10

Apr11

Apr12

Apr13

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

EBIT

Get a 7-Day Free Trial

-3.04

-3.84

-4.62

-4.93

-2.06

Cotinga Pharmaceuticals Quarterly Data
	Apr15	Jul15	Oct15	Jan16	Apr16	Jul16	Oct16	Jan17	Apr17	Jul17	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20
EBIT	Get a 7-Day Free Trial															-0.27	-0.69	-0.39	-0.37	-0.36

Competitive Comparison of Cotinga Pharmaceuticals's EBIT

For the Biotechnology subindustry, Cotinga Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cotinga Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cotinga Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cotinga Pharmaceuticals's EV-to-EBIT falls into.

Cotinga Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jan. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.81 Mil.

Cotinga Pharmaceuticals (OTCPK:COTQF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cotinga Pharmaceuticals's annualized ROC % for the quarter that ended in Jan. 2020 is calculated as:

	ROC % (Q: Jan. 2020 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Oct. 2019 )	+	Invested Capital (Q: Jan. 2020 ))	/ count )
=	-1.44 * ( 1 - 0% )	/	( (0.79	+	0.878)	/ 2 )
=	-1.44	/	0.834
=	-172.66 %

where

	Invested Capital		(Q: Oct. 2019 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.715	-	3.011	-	( 0.026	-	max(0, 3.269	-	0.183	+	0.026	))
=	0.79

	Invested Capital		(Q: Jan. 2020 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.695	-	3.319	-	( 0.035	-	max(0, 3.677	-	0.175	+	0.035	))
=	0.878

Note: The Operating Income data used here is four times the quarterly (Jan. 2020) data.

2. Joel Greenblatt's definition of Return on Capital:

Cotinga Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2020 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jan. 2020 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Oct. 2019		Q: Jan. 2020
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.44	/	( ( (0 + max(-2.855, 0))	+	(0 + max(-3.18, 0)) )	/	2 )
=	-1.44	/	( ( 0	+	0 )	/	2 )
=	-1.44	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Oct. 2019 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.155)	-	(3.011	+	0	+	-0.00099999999999989)
=	-2.855

	Working Capital		(Q: Jan. 2020 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.138)	-	(3.319	+	0	+	-0.00099999999999989)
=	-3.18

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jan. 2020) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cotinga Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jan. 2020 )
	=	-1.814	/	0.333
	=	-544.74 %

Cotinga Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1

Website

http://www.cotingapharma.com

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Headlines

From GuruFocus

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire • 05-22-2019

Cotinga Pharmaceuticals Reports Fiscal 2018 Third Quarter Financial and Operating Results

By GlobeNewswire GlobeNewswire • 04-03-2018